Intuitive Surgical, Inc. (ISRG) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $1.60 per share a year ago.
Intuitive Surgical beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its surgical robots used in minimally invasive procedures.
Intuitive Surgical (ISRG) reported fourth-quarter earnings that topped analysts' expectations as it boosted sales of its surgical robots.
Intuitive Surgical stock skidded late Thursday despite beating profit expectations following a strong sales preannouncement that sent shares on a sprint. The post Robotic Surgery Titan Intuitive Surgical Slips On Conservative, But Expected, Guidance appeared first on Investor's Business Daily.
Shares of robotic surgery pioneer Intuitive Surgical (ISRG -0.29%) have been soaring lately. A preliminary look at sales results from the fourth quarter of 2024 suggests its business is on the right track.
Intuitive Surgical, Inc. ISRG is announcing its fourth-quarter earnings on Thursday. Wall Street expects $1.79 in EPS and $2.25 billion in revenues as the company reports after market hours.
Intuitive Surgical scheduled to report earnings after Thursday's close. The stock hit a record high of $614.72/share on Wednesday.
Intuitive Surgical's fourth-quarter results are likely to reflect solid performance in the company's Instruments & Accessories segment. Improving margins buoy optimism.
Intuitive Surgical (ISRG 1.94%) is a healthcare company that makes robotic-assisted surgical devices. Its da Vinci surgical systems can assist surgeons make minimally invasive and precise procedures, which can help save lives and improve outcomes for patients.
Leading robotic surgery systems developer Intuitive Surgical Inc. NASDAQ: ISRG kicked off the new year by issuing upside guidance for its fourth quarter of 2024. Its da Vinci Surgical System has had a first-mover advantage ever since it launched in 2000, becoming the first commercial robotic surgical platform approved by the FDA.
Intuitive Surgical's share price surged after the company reported 25% YoY revenue growth in the fourth quarter. Despite macro headwinds, robust procedure volumes, international expansion and new product rollouts continue to support growth. While investors probably should look through the current growth surge, particularly given Intuitive's extreme valuation, near term earnings beats could continue to drive the stock higher.
You can look at the momentum for some stocks and have a feeling that it's about to end. Others, though, have such strong underlying business prospects that they're practically unstoppable.